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Abstract Astrocytes abound in the human central nervous
system (CNS) and play a multitude of indispensable roles in
neuronal homeostasis and regulation of synaptic plasticity.
While traditionally considered to be merely ancillary support-
ive cells, their complex yet fundamental relevance to brain
physiology and pathology have only become apparent in re-
cent times. Beyond their myriad canonical functions, previ-
ously unrecognised region-specific functional heterogeneity
of astrocytes is emerging as an important attribute and chal-
lenges the traditional perspective of CNS-wide astrocyte ho-
mogeneity. Animal models have undeniably provided crucial
insights into astrocyte biology, yet interspecies differences
may limit the translational yield of such studies. Indeed, ex-
perimental systems aiming to understand the function of
human astrocytes in health and disease have been hampered
by accessibility to enriched cultures. Human induced pluripo-
tent stem cells (hiPSCs) now offer an unparalleled model sys-
tem to interrogate the role of astrocytes in neurodegenerative
disorders. By virtue of their ability to convey mutations at
pathophysiological levels in a human system, hiPSCs may
serve as an ideal pre-clinical platform for both resolution of
pathogenic mechanisms and drug discovery. Here, we review
astrocyte specification from hiPSCs and discuss their role in
modelling human neurological diseases.
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Introduction
Astrocytes are specialised cells that are classified as central
nervous system (CNS) glia, together with oligodendrocytes
and microglial cells. During development, the specification
of glia (gliogenesis) follows that of neurons (neurogenesis).
In the late embryonic stage and early postnatal period, astro-
cyte precursors are specified from neural precursor cells
(NPCs) via Notch signalling [1]. In a process that is reminis-
cent of neuronal development, astrocyte precursors migrate
away from germinal zones in a radial manner before they
differentiate and mature, acquiring unique region-specific
functional attributes [2]. Once fully mature, astrocytes occupy
largely non-overlapping three-dimensional domains, allowing
for functional compartmentalisation within the neuraxis [3].
At the boundaries between domains, gap junctions are formed
to facilitate the spread of ions and signalling molecules across
the astrocyte network [4]. The complexity of mature astro-
cytes is structurally exhibited by up to eight major (or ‘stem’)
processes, each of which gives rise to hundreds of thousands
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of fine, elaborated subprocesses or ‘leaflets’ that intimately
contact synapses, dendrites and blood vessels [5–8]. Such
arborisation is crucially related to the diverse roles played by
astrocytes, together with the careful harmonisation and func-
tional coupling of these activities.
Each astrocyte can contact up to a million individual syn-
apses [9]. During development, astrocytes control the forma-
tion, maturation and elimination of synapses [10]. In the adult
brain, perisynaptic astrocytic processes intimately enwrap
dendritic spines and presynaptic terminals forming the tripar-
tite synapse, which in turn allows astrocytes to respond to
synaptic activity and regulate synaptic transmission [5, 6,
11]. By bridging connections between neurons, other glial
cells and the vasculature, astrocytes control a number of ho-
meostatic processes. These include the supply of glucose and
lactate as energy sources for neurons and the regulation of
extracellular pH, ion and neurotransmitter concentration
throughout the brain [12, 13]. Through contact with blood
vessels, astrocytes regulate blood flow in response to the met-
abolic activity of different brain areas [14]. By virtue of these
homeostatic functions, astrocytes strongly reinforce neuronal
survival and function.
Although reports on a precise neuron/glia ratio in the brain
vary, the consensus view is that in the human brain they exist
in equivalent numbers, with astrocytes comprising up to 40 %
of all CNS cells [15]. Region-specific differences in this ratio
are likely to have functional consequences; for example, as-
trocytes outnumber neurons in the cortex, which is in contrast
to the ratio within the cerebellum. Recognition of profound
heterogeneity is important when considering the role of astro-
cyte structure and function in disease [16].
Region-Specific Structure and Function of Astrocytes
Classical taxonomy codifies astrocytes into protoplasmic and
fibrous subtypes, which are found in the grey and white mat-
ter, respectively [17]. While these descriptions retain validity,
accumulating data from genetic and lineage-tracing ap-
proaches have highlighted substantial astrocyte heterogeneity
(both morphological and functional), raising the prospect of
taxonomic reclassification to reflect this previously under-
recognised diversity [2, 18–20]. Astrocytic heterogeneity be-
yond protoplasmic and fibrous subtypes is partially reflected
in their morphological status including radial glia of the de-
veloping brain (later forming the Muller glia of the retina,
Bergmann glia of the cerebellum or stellate astrocytes else-
where), velate astrocytes of the cerebellum, cortical interlam-
inar astrocytes, tanycytes in periventricular areas, pituocytes
in the neurohypophysis and perivascular astrocytes.
Additionally, ependymal cells, retinal pigment epithelium
and cells constituting the choroid plexi have also been broadly
considered as belonging to the astrocyte lineage. In addition to
this morphological heterogeneity, astrocytes exhibit
considerable functional diversity in their expression of neuro-
transmitter receptors, ion channels, transporters and other
molecules. For example, cortical astrocytes express high
levels of GLT-1 and moderate levels of GLAST [21], while
spinal cord astrocytes express significantly lower levels of
GLT-1 [22] but specifically express glycine receptors.
Inward rectifying potassium channels are also differentially
expressed in astrocytes in a region-specific fashion, with
Kir4.1 being more abundant in the ventral spinal cord com-
pared to the dorsal regions [23]. In the ventral mesencephalon,
but not in other parts of the CNS, astrocytes express Wnts that
locally regulate the generation of dopaminergic neurons [24]
and dopamine receptors. Similarly, the expression of Sema3a
by ventral spinal cord astrocytes is required for proper senso-
rimotor circuit organization and function [25]. Such regionally
determined functional heterogeneity is central to understand-
ing the pathogenesis of region-specific neurological disease
[26••]. It follows that the generation of region-specific astro-
cytic populations is crucial to accurately determine their role
in disease.
The Need for a Human Astrocyte Experimental Platform
Accumulating evidence of a multitude of astrocyte-mediated
homeostatic processes has challenged traditional ‘neuron-cen-
tric’ views of neurological disease. Indeed, several studies
have highlighted the relevance of non-cell autonomous
astrocyte-dependent mechanisms in neurodegenerative disor-
ders [27]. In recent years, animal models have provided fun-
damental insights into the role of astrocytes in neurodegener-
ation. Notwithstanding the undeniable utility of animal
models, complementary platforms to investigate astrocyte bi-
ology in human systems are necessary in order to more pre-
cisely capture clinical pathophysiology by avoiding potential
interspecies differences. Indeed, an increasing body of evi-
dence suggests that significant differences exist between hu-
man and rodent astrocytes. Human astrocytes have a more
complex structure than their rodent counterparts, occupying
an almost 30-fold larger volume, and extending 10-fold more
processes [28, 29]. This structural complexity is also reflected
in functional properties, which are not shared by astrocytes of
other species. For example, mature human astrocytes propa-
gate calcium waves more rapidly than their rodent counter-
parts [29, 30, 31••] and show a more robust response to glu-
tamate [31••, 32], consistent with an increased capacity to
sense and respond to synaptic activity. Chimeric mice receiv-
ing transplants of human astrocyte precursors show increased
levels of excitatory synaptic transmission, enhanced long-
term potentiation (LTP) and improved learning and memory
[30]. The difference between human and rodent astrocytes is
also reflected in their transcriptome, with over 600 genes be-
ing enriched in human but not mouse astrocytes. Among these
differentially expressed genes, common themes emerge
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including divergent calcium handling properties, as alluded to
above [31••]. In view of the limited accessibility to human
non-transformed astrocytes for disease modelling, patient-
specific human induced pluripotent stem cells (hiPSCs) rep-
resent an attractive strategy to derive highly enriched astrocyt-
ic populations for further study.
Specification of Astrocytes from hiPSCs: A
Developmental Perspective
Astrocytes are differentiated from hiPSCs using
ontogeny-recapitulating methods, in a similar fashion
to their region-specific neuronal counterparts. It is note-
worthy that astrocyte development is comparatively
understudied and poorly defined, partially due to the
lack of reliable markers [33–35]. Protocols for generat-
ing astrocytes from hiPSC are broadly operationalised
in four main phases: (1) the neural induction phase,
when hiPSCs lose their pluripotency and are converted
into NPCs; (2) neural patterning to positionally specify
astrocytes to defined regions of the CNS; (3) the
gliogenic switch, which marks the transition of NPCs
from neurogenic to gliogenic—a temporally determined,
cell intrinsic and likely epigenetically mediated process
and (4) astrocyte terminal differentiation, during which
gliogenic precursors terminally differentiate into astro-
cytes (Fig. 1a). These phases are discussed in further
detail hereunder.
Neural Induction
HiPSCs a r e f i r s t conve r t ed in to mu l t i po t en t
neuroepithelial cells in a process defined as neural in-
duction. The more robust protocols for neural induction
rely on dual inhibition of SMAD signalling in adherent
hiPSC cultures [36]. These protocols eliminate the use
of stromal feeders and avoid the formation of embryoid
bodies [37, 38], providing a reliable platform to achieve
efficient neural conversion in chemically defined medi-
um. During neural conversion, the downregulation of
pluripotency genes, such as Nanog and Oct4, is mir-
rored by the acquisition of neural stem cell markers
including Pax6 and nestin [36]. In parallel, a morpho-
logical transition from hiPSCs with large nuclei to a
tightly packed neuroepithelial sheet with notably smaller
nuclei is observed. Neuroepithelial differentiation can
also be confirmed by the appearance of neural rosettes
[36]. The newly generated NPCs can be maintained ei-
ther in adherent monolayer or suspension culture, and
they can be expanded in vitro in the presence of growth
factors such as fibroblast growth factor 2 (FGF-2) or
epidermal growth factor (EGF) [39].
‘Patterning’ Strategies to Generate Region-Specific
Astrocytes
Awealth of region-specific functional neuronal subtypes have
been specified from hiPSCs (reviewed in [40, 41]), although
certain cell fates remain challenging, including cerebellar de-
rivatives [42]. Comparatively less experimental attention has
been directed towards glia. Recent evidence suggests that
morphological and functional astrocyte diversity is deter-
mined during development by regional patterning of neural
precursors, thus allowing similar developmental principles to
be applied for their specification from hiPSCs [18, 35, 43].
In vitro, the default regional identity acquired by hiPSC-
derived NPCs is a telencephalic [44]. After neural conversion,
newly generated NPCs can be patterned along rostro-caudal
and dorso-ventral axes using extrinsic morphogenetic instruc-
tion. The administration of FGF and retinoic acid (RA) deter-
mines rostro-caudal identity [43, 45]. Wnts, bone morphoge-
netic proteins (BMPs) and sonic hedgehog (Shh) are utilised
to specify NPCs along the dorso-ventral axis [44], although
the actual effects of each morphogen are more complex and
context-dependent. It was recently shown that the positional
identity acquired during patterning is retained at later stages of
astroglial specification—described below—as confirmed by
expression of homeodomain-specific transcription factors
[35, 43, 46, 47]. This approach therefore provides a powerful
platform to generate region-specific astrocytes. Further exper-
imentation is required to realise the full morphological and
phenotypic diversity of astrocytes in the CNS. The develop-
ment of in vivo visualisation tools and high-throughput
transcriptomic approaches raise the prospect of a more inte-
grated morphological and functional classification that cap-
tures the true complexity of astrocyte heterogeneity [48].
The Gliogenic Switch
Neurogenesis precedes gliogenesis in vivo, with precursors
switching developmental programmes from the production
of neurons to the generation of glial cells. This process, known
as the gliogenic switch, depends on two related events: the
inhibition of neurogenesis and the activation of gliogenesis.
Understanding the mechanisms underlying the gliogenic
switch is crucial to define optimal strategies for differentiating
astrocytes from hiPSC-derived NPCs. A key element with
dual function in the gliogenic switch is Notch signalling
[49]: on the one hand, Notch inhibits proneural basic helix
loop helix (bHLH) factors via HES proteins. On the other
hand, it promotes astrogliogenesis by activating the JAK-
STAT pathway [50], a key regulator of astrocyte development
[51]. Together with Notch, several cytokines secreted by dif-
ferentiating neurons also converge on the JAK-STAT path-
way, thus promoting astrocyte specification; these include
members of the interleukin 6 (IL-6) family, such as leukaemia
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inhibitory factor (LIF), ciliary neurotrophic factor (CNTF) and
cardiotrophin 1 (CT1) [52]. BMPs also synergistically interact
with these cytokines, inducing the formation of a Smad1-
STAT3 complex that transactivates astrocyte-associated genes
[53], while also inhibiting proneural bHLH transcription fac-
tors [54]. Together with Notch, nuclear factor I (NFI) genes,
and in particular NFIA, have an instructive role in promoting
astrogliogenesis, by directly regulating the expression of the
astrocyte genes GFAP [55] and GLAST [56]. For NPCs to
acquire gliogenic competence, key epigenetic changes occur
including a wave of de-methylation of astrocyte-specific
genes, which regulates the switch from early (neurogenic) to
late (gliogenic) precursors in the developing rodent brain [51,
57, 58]. Accordingly, global DNA hypomethylation leads to
the activation of the JAK-STAT pathway and induces preco-
cious astrogliogenesis, both in vitro and in vivo [59].
Recapitulating these developmental milestones, NPCs
derived from hiPSCs initially have high neurogenic po-
tential and limited capability to generate glial cells [43],
possibly due to hypermethylation of astrocyte genes
[60]. Indeed, early NPCs (2–4 weeks of differentiation
in vitro) would spontaneously differentiate into neurons
upon growth factor withdrawal [36, 61]. However, after
long-term expansion in vitro, in the presence of FGF
and/or EGF, NPCs spontaneously undergo the gliogenic
switch. This results in a progressive reduction of their
neurogenic potential, paralleled by an increased compe-
tence to generate astrocytes. Under these conditions, and
by around 12–15 weeks, the majority of precursors are
positive for the immature astrocyte markers NFIA,
S100β and CD44 [35, 39, 43]. While remaining prolif-
erative, these cells express the glutamate transporter
GLT-1 (known as EAAT-2 in humans), possess potassi-
um currents and can induce synaptogenesis—all features
consistent with an immature astrocytic phenotype [43].
At this stage, immature astrocytes are also responsive to
signals inducing their terminal differentiation and
maturation.
Fig. 1 Modelling neurodegeneration using hiPSC-derived astrocytes. a
Diagram of directed differentiation of astrocytes from hiPSCs. HiPSCs
are initially converted into rosette-forming neuroepithelial cells. After
neural conversion, morphogens can be added for regional patterning of
NPCs. NPCs can be subsequently expanded either in adhesion or in
suspension in presence of growth factors. Early neurogenic progenitors
will spontaneously differentiate into neurons upon growth factor with-
drawal. To generate astrocytes, long-term expansion (>60 days) of NPCs
is required to allow the gliogenic switch to occur. Terminal differentiation
may be accelerated using morphogens or epigenetic modulators. Markers
for the different stages of differentiation are listed in the corresponding
boxes. b Schematic representation of the possible involvement of astro-
cytes in neurologic conditions. Diseased astrocyte can directly be harmful
to neurons via the release of toxic factors such as inflammatory mediators
and ROS (1). Alternatively, an astrocyte cell-autonomous pathology
could impair their homeostatic and trophic functions, resulting in neuro-
nal damage due to lack of support (2). Lastly, an intrinsic abnormality of
astrocyte development could alter neuronal maturation and function (3).
Diagrams were drawn using templates freely available from Servier
Medical Art (http://www.servier.co.uk/content/servier-medical-art)
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Promoting Terminal Differentiation
Immature proliferative astrocytes can be induced to spontane-
ously differentiate by removing mitogens from the culture
medium [39]. Despite generating a highly enriched astrocyte
culture, this method requires protracted culture durations
(>120–180 days). For this reason, developmental insights
have been exploited to accelerate functional maturation of
gliogenic precursors/immature astrocytes. Such strategies in-
clude the use of: (1) interleukins of the IL-6 family such as
CNTF [43, 62, 63••] and LIF [64]; (2) BMPs, alone or in
combination with the aforementioned cytokines [64, 65] and
(3) neuregulin, which also activates the JAK-STAT pathway
[65]. Others have reported the use of serum to induce efficient
terminal differentiation of astrocytes [46, 66]. However, se-
rum is known to induce irreversible reactive changes in cul-
tured astrocytes [19, 31••, 67]. Interestingly, and in contrast to
other studies showing that FGF-2 maintains immature astro-
cytes in a proliferative state, one report demonstrated that
FGF-1 and FGF-2 can induce the differentiation of mature
quiescent astrocytes with low GFAP expression but high
levels of the glutamate transporter GLT-1 [46]. Lastly, based
on the epigenetic changes that accompany the gliogenic
switch in vivo [51], modifiers such as the DNA methyltrans-
ferase inhibitor Aza-Cytidine and the histone deacetylase in-
hibitor Trichostatin-A have been used to accelerate astrocyte
differentiation from NPCs [60].
Characterisation of hiPSC-Derived Astrocytes
One of the most pressing issues regarding the characterisation
of hiPSC-derived astrocytes is the lack of reliable markers
defining different astrocytic subtypes and their stage of matu-
ration. Generally, precursors committed to the astrocyte line-
age and immature astrocytes are characterised by the expres-
sion of the transcription factor NFIA [55, 56]. S100β has also
been widely used as an astrocyte progenitor marker; however,
it is also expressed in oligodendrocyte precursors/NG2 cells
[68]. For some time, GFAP has been considered a gold stan-
dard marker for mature astrocytes; however, its expression
varies dramatically depending on regional identity, activation
state and ageing [69]. Therefore, in parallel to GFAP, other
markers should be considered including ALDH1L1, CD44,
GLT-1, GLAST, Acquaporin4 and Connexin43 [26••, 31••,
70].
In addition to assessing the expression of specific markers,
several assays are available to characterise the functional
properties of hiPSC-derived astrocytes. It is therefore possible
to assess whether patient-specific hiPSC-derived astrocytes
show any intrinsic defect or cell autonomous pathology, there-
by recapitulating a specific disease-related phenotype. This
can be carried out by morphological analyses, examining the
number, volume and length of astrocytic processes [31••,
71••]. Astrocytes can also be tested functionally by measuring
their electrophysiological properties, glutamate uptake, calci-
um wave propagation upon mechanical stimulation and calci-
um signalling in response to ATP and glutamate [26••, 31••,
43, 63••, 72•]. On the other hand, non-cell autonomous effects
of hiPSC-derived astrocytes on maturation, function and sur-
vival of neurons can be evaluated using co-culture or astrocyte
conditioned media paradigms. A classical assay makes it pos-
sible to assess immature astrocytes’ ability to induce synapse
formation and maturation, using co-culture with retinal gan-
glion cells, mouse or human neurons [31••, 63••, 72•]. Co-
culture also allows evaluation of the astrocyte’s impact on
neuronal viability, providing a simplified in vitro system to
investigate signalling pathways involved in a neuroprotective
or toxic effect of these cells [31••, 73•]. Lastly, to analyse cell-
cell interactions in a more complex environment, hiPSC-
derived astrocytes can be transplanted into rodent models,
assessing their integration and function in vivo [43, 65]. The
approaches described above allow the generation of highly
enriched astrocyte cultures that represent a powerful tool to
investigate developmental and disease-related molecular
mechanisms. For experimental use, it is important to consider
both the state of astrocytic maturation and reactivity as these
may influence experimental outcomes.
Astrocyte Maturation
Astrocytes exist in two distinct maturational stages: (1) foetal,
during which they are immature and proliferative and (2) a
postnatal phase when astrocytes exit the cell cycle and termi-
nally differentiate [31••, 46, 70, 74]. Astrocytes maximally
express markers of maturity after 6–12 months of age in
humans [31••]. As astrocytes mature, their gene expression
profile changes dramatically with an upregulation of genes
involved in synaptogenesis, cell-cell signalling, fatty acid me-
tabolism, cell adhesion and ion homeostasis [31••], suggesting
that they exhibit differential functional competencies that are
determined by maturational state. Importantly, the temporal
coincidence of astrocytic maturity with synaptogenesis under-
lies their pivotal role in orchestrating the formation of neuro-
nal connections, not just during development but for the dy-
namic synaptic remodelling that occurs throughout adult life.
When astrocytes are generated in vitro from hiPSCs, they are
likely to reflect a foetal maturational state, as already demon-
strated for their hiPSC-derived neuronal counterparts [75–77].
Each hiPSC-derived astrocyte culture is also likely comprised
by a mixture of cells at different stages of differentiation,
ranging from precursors to mature astrocytes [26••].
Additionally, pure astrocytic cultures lack instructive develop-
mental signals from other neural cells that would otherwise be
present in vivo, which might affect the expression of
astrocyte-specific proteins [78]. In light of the significant
functional differences between immature and mature
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astrocytes in physiological and pathological conditions, the
appropriate experimental paradigm should be carefully con-
sidered to capture specific and experimentally relevant
phenotypes.
Astrocyte Reactivity
Astrocytes in culture often resemble those responding to CNS
injury and are collectively termed ‘reactive astrocytes’. This
state encompasses a number of attributes including astrocyte
proliferation, hypertrophy, structural and functional remodel-
ling of their processes. For many decades, reactive astrocytes
have been regarded as detrimental for repair; however, recent-
ly, it is increasingly recognised that they also choreograph
neurorestorative processes [69, 79]. These responses are com-
plex and dynamic over each disease course, and can include
varying degrees of the following injury-specific effector
mechanisms: immunoregulation, functional lesion isolation,
neurovascular reconfiguration and adaptation of neuronal con-
nectivity [80•]. It transpires that the specific repertoire of mor-
phological and functional changes that accompany astrocytic
reactions is determined by the extent, nature and anatomical
location of the injury. At the lesion site, robust astroglial struc-
tural and functional changes occur, leading to disruption of
domain architecture and accumulation of inflammatory cells,
precursors and meningeal fibroblasts, which conspire to form
the glial scar (this process is termed ‘anisomorphic
astrogliosis’). This is associated with production of substances
that may inhibit axonal regeneration and neurite growth, in-
cluding chondroitin sulphate proteoglycans. Conversely, as-
trocytic response in mild insults, or remotely from the injury
site, causes far less structural change (termed ‘isomorphic
astrogliosis’). Despite a less conspicuous morphological cel-
lular change, these astrocytes exhibit more favourable func-
tional changes, which are associated with neuroprotection,
axon repair and synaptic plasticity [81, 82]. Against this back-
ground, and depending on the experimental paradigm, either
resting or reactive astrocytes (or both) may be required for
specific assays. Most of the soluble factors used to accelerate
astrocyte differentiation in vitro, such as cytokines and BMPs,
are also effective inducers of astrocyte reactivity and can in-
duce irreversible alterations of astrocytic function [83]. While
reactive astrocytes might recapitulate the response to a specif-
ic pathological condition, prolonged exposure to activating
stimuli could alter or even mask disease phenotypes [26••].
If the experimental paradigm requires a more physiological
model of accelerated astrocyte maturation in the absence of
activation, a recent report suggests the use of FGF-1 to induce
a quiescent mature phenotype [46]. In neurological disease,
however, astrocytes predominantly show some form of reac-
tive transformation in affected areas, therefore reverting them
into a quiescent phenotype in vitro may actually impede
modelling neurodegeneration with fidelity and precision.
Modelling Neurodegeneration
Noting the complexity of astrocyte-mediated homeostatic
functions, their implication in a number of CNS disorders is
somewhat unsurprising. Whether astrocyte contribution to
disease onset and progression is due to a loss of their support-
ive and homeostatic function, or to a gain of toxic functions—
or a combination of both—remains unresolved in the majority
of neurodegenerative conditions (Fig. 1b) [27]. The use of
patient-specific hiPSC-derived astrocytes therefore represents
a powerful tool to address this question, by recapitulating
initiating pathogenic events against a human genetic back-
ground, where mutations are conveyed at pathophysiological
levels. Here, we review recent progress in the field with a
specific focus on studies using hiPSC-derived astrocytes to
interrogate their role in neurodegeneration (further
summarised in Table 1).
Amyotrophic Lateral Sclerosis (ALS)
ALS is a progressive neurodegenerative disease characterised
by selective degeneration of both upper and lower motor neu-
rons (recently reviewed in [91]). Early astroglial atrophy is
reported in the immediate vicinity of spinal motor neurons—
prior to their degeneration—in animal models of SOD1-
related ALS [92]. Indeed, since the observation that loss of
the astrocytic glutamate transporter GLT-1 leads to motor neu-
ron death by excitotoxicity [93, 94], converging lines of evi-
dence have demonstrated that astrocytes contribute to disease
progression in a non-cell autonomous manner [95]. Using
hiPSC-derived astrocytes from patients with familial and spo-
radic ALS, some studies have attempted to elucidate non-cell
autonomous pathogenic mechanisms. In one study, astrocytes
were directly reprogrammed from ALS patients carrying
C9ORF72 hexanucleotide expansion, mutations in SOD1
and sporadic cases. ALS-astrocytes, either from familial or
sporadic cases, were found to be deleterious to both motor
neuron survival and neurite outgrowth in co-culture para-
digms. To determine whether this effect was dependent on
ALS-astrocyte toxicity versus lack of support, co-cultures
were supplemented with wild-type astrocyte conditioned me-
dium. This approach failed to rescue motor neuron cell death,
suggesting a toxic gain of astrocytic function [73•]. HiPSC-
derived astrocytes from patients carrying TARDBP mutations
show abnormalities typical of a TDP-43 proteinopathy, in-
cluding its cytoplasmic mislocalisation. Longitudinal imaging
of mutant astrocytes revealed that TDP-43 mislocalisation de-
creases cell survival, suggesting that mutant TDP-43 is re-
sponsible for astrocyte pathology. In this case, however, when
co-cultured with either control or mutant TARDBP motor
neurons, mutant astrocytes were not toxic [63••]. This result
is in apparent contrast with the non-cell autonomous toxicity
previously reported in the context of sporadic, C9ORF72 and
Curr Stem Cell Rep (2016) 2:236–247 241
SOD1mutations [73•, 96–98]. However, these findings can be
reconciled through the possibility of mutation-specific astro-
cyte pathology in familial ALS, therefore suggesting at least
partially divergent disease mechanisms in astrocytes. Further
systematic astrocyte-neuron interaction studies are essential to
precisely elucidate key aspects of cellular autonomy in vitro
Table 1 Summary of studies using hiPSC-derived astrocyte to investigate disease mechanisms
Disease Mutated
gene(s)
Culture method Astrocyte phenotype Effect on neurons Ref.
AD APP Neural conversion with formation of
embryoid bodies. Expansion of
NPCs in presence of BDNF and
GDNF. Terminal differentiation
induced by 10 % serum
Intracellular accumulation of Aβ,
increased ROS production, ER
stress
N/A [84]
ALS SOD1,
C9orf72,
sporadic
cases
Direct reprogramming of patient
fibroblast to iNPCs. Terminal
differentiation induced by
10 % serum
No astrocyte pathology observed Reduced neurite outgrowth and neuronal
survival in co-cultures
[73•]
TARDBP iPSC-derived NPCs expansion in
suspension in presence of EGF
and FGF-2
Terminal differentiation induced
by CNTF
Cytoplasmic accumulation of TDP-
43, reduced astrocyte survival
No toxicity [63••]
CS HRAS iPSC-derived NPCs expansion in
suspension in presence of EGF
and FGF-2
Terminal differentiation induced by
CNTF. Astrocytes analysed after
7 days of terminal differentiation
Accelerated astrocyte maturation,
hyperplasia, increased release of
proteoglycans and extracellular
matrix components
In co-culture, premature maturation of
neurons, increased neurite outgrowth
and increased synaptic density
[71••]
DS Trisomy of
Chr 21
iPSC-derived NPCs expansion in
suspension in presence of FGF-2.
Terminal differentiation induced
by FGF2 and BMP4
Enhanced astrocyte differentiation.
Higher expression of GFAP and
S100β, increased production of
ROS, decreased expression of
synaptogenic molecules
In co-culture, reduced neuronal survival,
reduced ion channel maturation and
synapse formation
[72•]
HD Htt iPSC-derived NPCs expansion in
suspension in presence of FGF-2.
Terminal differentiation induced
by 2 % serum
Astrocyte vacuolation N/A [85]
RS MECP2 iPSC-derived NPCs expansion in
suspension in presence of FGF-2.
Terminal differentiation induced
by
growth factors withdrawal
Enhanced astrocyte differentiation.
Higher expression of GFAP and
S100β.
N/A [86]
MECP2 iPSC-derived NPCs expansion in
adhesion in presence of FGF-2.
Terminal differentiation induced
by CNTF
Altered microtubule dynamics.
Impaired vesicular transport
N/A [87]
MECP2 iPSC-derived NPCs expansion in
suspension in presence of EGF
and FGF-2. Terminal
differentiation
induced by CNTF
No phenotype described. In co-culture, mouse hippocampal
neurons show reduced neurite
outgrowth and reduced frequency of
postsynaptic currents
[88]
SMA SMN1 iPSC-derived NPCs expansion in
suspension in presence of EGF
and FGF-2. Terminal
differentiation
induced by CNTF
Increased GFAP expression,
decreased process length,
impaired calcium signalling
N/A [89]
SMN1 iPSC-derived NPCs expansion in
suspension in presence of EGF
and FGF-2. Terminal
differentiation
induced by growth factor
withdrawal
No alteration of mitochondrial
bioenergetics and oxidative
stress markers
N/A [90]
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using functional and high-throughput molecular assays in
hiPSC systems.
Alzheimer’s Disease (AD)
AD is the most common cause of dementia and is
characterised by a progressive decline in cognitive functions,
especially episodic memory. Histopathologically AD brains
show characteristic deposition of intra-neuronal neurofibril-
lary tangles and extracellular β-amyloid (Aβ) plaques.
Reactive astrocytes are found in association with Aβ plaques,
but their contribution to disease progression is still unclear
[99]. Astrocytes can internalise and degrade extracellular Aβ
via ApoE [100, 101]. However, the intracellular accumulation
of Aβ in mouse astrocytes results in abnormal calcium influx
and glutathione depletion. This reduction of the antioxidant
defence in astrocytes results in impaired neuronal viability
after exposure to Aβ oligomers, suggesting that neuronal cell
death in this model is a consequence of impaired astrocytic
ability to support neuronal survival [102]. Additionally, a re-
cent study describes cell-autonomous pathology in both
hiPSC-derived neurons and astrocytes from patients with ei-
ther familial or sporadic AD. AD astrocytes showed intracel-
lular accumulation of Aβ, increased ER stress and ROS pro-
duction. However, the effect of AD astrocytes on neuronal
function and survival was not directly examined [84].
Parkinson’s Disease (PD)
PD is a neurodegenerative disease that presents with both
motor and non-motor phenomena. Motor hallmarks include
asymmetrical slowing of movements (bradykinesia), rigidity,
tremor and postural instability. Although the neuropathologi-
cal manifestations can be extensive, motor perturbations are
anatomically localised to the substantia nigra and more spe-
cifically to dopaminergic neurons. The pathological hallmarks
of PD include Lewy bodies, which are composed of α-synu-
clein. Neuron to astrocyte transfer of α-synuclein has been
demonstrated along with evidence of astrocyte-related non-
cell autonomous mechanisms of injury [103]. Conversely,
astrocyte-specific overexpression of Nrf2 andDJ-1 (regulators
of protective responses against cellular/mitochondrial oxida-
tive stress) ameliorate cellular phenotypes [104, 105]. Taken
together, these facts demonstrate dynamic and crucial roles for
astrocytes in PD. The astrocyte to neuron ratio for dopaminer-
gic neurons in the substantia nigra has been suggested to be
lower than any other region within the neuraxis [106], raising
the hypothesis that these neurons are more vulnerable to
perturbed glial support. Systematic studies have yet to com-
prehensively address the role(s) of region-specific astrocytes
in PD and this is an important focus for future hiPSC-based
studies.
Huntington’s Disease (HD)
HD is a rare neurodegenerative disorder caused by the expan-
sion of a CAG repeat in the huntingtin (HTT) gene. Despite
having been historically considered a strictly neuronal pathol-
ogy, recent studies outline a key role for astrocytes in HD
pathogenesis. Expression of Htt with expanded CAG repeats
in mouse astrocytes manifest a functional atrophy as demon-
strated by impaired glutamate transport potentially leading to
excitotoxicity [107]. More recently it was shown that, in an
HD mouse model, mutant Htt causes the downregulation of a
potassium channel in astrocytes in the striatum, thus impairing
their ability to buffer extracellular potassium and increasing
the excitability of spiny neurons [108]. Whether these astro-
cytic phenotypes described in rodent models are also shared
by human astrocytes remains unknown. To date, only one
study has investigated the effects of mutant Htt in hiPSC-
derived astrocytes fromHD patients. This study reports exten-
sive astrocyte vacuolation that increases with time in culture
and correlates with the length of CAG expansion [85].
However, molecular mechanisms or functional implications
of this astrocytic phenotype have not been addressed.
Modelling Neurodevelopmental Disorders
In light of the instructive role of astrocytes during CNS devel-
opment, emerging evidence shows that these cells play a cru-
cial role in a number of neurodevelopmental disorders, such as
Costello syndrome (CS), Rett syndrome (RS) and Down syn-
drome (DS) [7]. Patient-specific iPSC-derived astrocytes
manifest developmental abnormalities that fundamentally af-
fect the morphology and function of neurons in a non-cell
autonomous manner. A common feature reported in these
studies is increased differentiation of NPCs towards the
astroglial lineage. Possibly the most striking example comes
from astrocytes generated from iPSC from patients with CS
[71••]. Compared to controls, these astrocytes showed a mark-
edly increased proliferation and accelerated maturation, more
complex morphology and hypertrophy. From a functional per-
spective, a major phenotype of these astrocytes is increased
deposition of extracellular matrix remodelling factors and pro-
teoglycans. This in turn culminates in premature maturation of
neurons in co-culture, and early formation of perineuronal
nets upon transplantation into mouse models of CS [71••].
Similarly, hiPSC-derived NPCs from RS patients showed en-
hanced astrocytic differentiation with increased expression of
GFAP and S100β [86]. Concurrently, altered microtubule dy-
namics and impaired vesicular transport were identified, sug-
gestive of an intrinsic RS astrocyte dysfunction [87]. In co-
culture with mouse hippocampal neurons, RS astrocytes have
a significant non-cell autonomous effect on neurons, both
morphologically and functionally. HiPSC-derived astrocytes
from RS patients cause an impairment in neurite outgrowth
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and soma size, with significant reduction in the frequency of
postsynaptic currents [88]. HiPSC-derived NPCs from DS
patients also exhibit increased generation of astrocytes under
spontaneous differentiation conditions, with a reciprocal de-
crease in neurogenesis. Due to reduced production of
synaptogenic molecules, DS astrocytes fail to induce full elec-
trophysiological maturation and synapse formation of
DS neurons. In addition, DS astrocytes also manifest
increased ROS production and lead to diminished survival
of DS neurons [72•]. Therefore, the hiPSC system can
yield valuable pathomechanistic information underlying
neurodevelopmental disorders.
Conclusions
At present, strategies for astrogliogenesis from hPSCs are
protracted and do not fully account for region-specific hetero-
geneity. Given the complex and diverse roles of astrocytes in
neurological disorders, greater experimental attention should
be paid to generating regionally defined subtypes of function-
ally mature astrocytes for further study. A number of impor-
tant experiments using human systems have uncovered astro-
cyte cell autonomous or non-cell autonomous mechanisms of
disease using neuron-astrocyte co-culture and astrocyte con-
ditioned media paradigms. It follows that astrocytes are
emerging as central players in neurodegeneration and their
systematic interrogation in conditions traditionally regarded
from a neuron-centric perspective is certainly warranted.
Given the intimate relationship of astrocytes with neuronal
synapses together with their abundance in the CNS, it is plau-
sible that they may provide an alternative cellular target for
mechanistically rationalised therapies. Recognising that each
model system has limitations, it is crucial to integrate human
in vitro systems with animal in vivo models and human post
mortem tissue to fully capture the complexity of human neu-
rological disorders. ‘Triangulating’ findings from this inte-
grated approach will in turn lead to high confidence data,
which can collectively overcome the limitations inherent in
each model system when employed in isolation. We feel
strongly that human experimental systems, such as hiPSCs,
are key to driving the necessary step change required to dis-
cover initiating molecular pathogenic events in neurodegener-
ation, which in turn will guide the development of desperately
needed mechanism-targeting therapies in this discipline.
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